Lam Research's Strong Quarter Masks Persistent China Risks and Valuation Overhang

What happened

A Seeking Alpha article published on March 12, 2026, touts Lam Research's AI-driven growth and strong FY2Q26 results, with revenue up 22% year-over-year to $5.34 billion and a 49.7% gross margin, alongside above-consensus guidance for the next quarter. The article emphasizes expanding market opportunities from GAA transistors, advanced packaging, and HBM4/NAND scaling, framing Lam as a beneficiary of a multi-year wafer fabrication equipment upcycle. However, the DeepValue master report critically notes that China revenue rose to 39% in the first half of FY26, with management warning that export controls have already materially impacted trade and pose a $600 million headwind for fiscal 2026. Despite operational strength, deferred revenue declined to $2.25 billion from $2.7 billion, signaling potential demand timing issues and reduced near-term visibility. At a P/E of 47.7x and EV/EBITDA of 46.0x, the stock embeds sustained high growth, leaving little tolerance for geopolitical or cyclical shocks.

Implication

The positive earnings and guidance reinforce the AI-driven growth narrative but fail to mitigate structural risks, including China's 39% revenue share and export-control headwinds that management admits could materially affect future sales. Declining deferred revenue from $2.7 billion to $2.25 billion indicates weakening customer down payments, potentially eroding revenue visibility and timing stability. At current multiples, the stock prices in a flawless upcycle, making it vulnerable to multiple contraction if China restrictions tighten or demand falters. Operational execution remains strong with gross margins near 50%, but this is already reflected in the valuation, requiring continued beats and de-risking to justify further gains. Therefore, investors should adhere to a WAIT approach, seeking entry near $200 or clearer evidence of reduced China dependency before increasing exposure.

Thesis delta

The new article does not alter the core thesis from the DeepValue report, which maintains a WAIT rating due to high valuation and China risks. It reinforces the bullish narrative but overlooks critical vulnerabilities like deferred revenue decline and policy-driven headwinds. Investors should view this as confirmation of near-term strength but remain vigilant for signs of margin compression or export-control escalation that could trigger a downgrade.